Trial Profile
The efficacy and tolerability of second-line bevacizumab + paclitaxel + carboplatin in elderly patients with advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2014
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 18 Mar 2014 New trial record